The updated edition of the New York Times bestseller from the chair of the Nu Skin Scientific Advisory Board reveals latest science behind measurable biology andThe updated edition of the New York Times bestseller from the chair of the Nu Skin Scientific Advisory Board reveals latest science behind measurable biology and

Dr. Joseph Chang Launches Update to Bestselling Book “The Aging Myth” With 15 More Years of Breakthrough Research on Cellular Wellness

2026/02/07 03:00
4 min read
For feedback or concerns regarding this content, please contact us at crypto.news@mexc.com

The updated edition of the New York Times bestseller from the chair of the Nu Skin Scientific Advisory Board reveals latest science behind measurable biology and evidence-based longevity

PROVO, Utah–(BUSINESS WIRE)–Nu Skin Enterprises Inc. (NYSE: NUS) today announced the relaunch of “The Aging Myth: Unlocking the Mysteries of Looking and Feeling Young,” the updated edition of the bestselling book from Dr. Joseph Chang, chair of Nu Skin’s Scientific Advisory Board. The relaunch marks a significant milestone in the evolution of evidence-based beauty and wellness, bringing together decades of research that underpin Nu Skin’s science-led innovations — from ageLOC® technology to the company’s intelligent beauty and wellness platform centered on Prysm iO™.

Originally published in 2011, “The Aging Myth” challenged conventional wisdom by proving that aging isn’t about genetic destiny, but about how our genes function. It helps readers understand the science behind their healthspan, or the number of healthy years they live. As people live longer, the concept of wellness is becoming focused on the quality of health during those years. The book quickly became a hit, reaching #2 on The New York Times Best Seller List in its first week and securing the #1 spot at Barnes & Noble, and top rankings on Amazon, Borders and The Wall Street Journal best seller lists.

“The fundamental premise remains unchanged: we are not prisoners of our genetics,” said Dr. Chang. “However, the science of aging has evolved tremendously since 2011. This updated edition reflects over 15 years of additional research that continues to validate our core message: aging is biology in motion, and biology can be influenced. When wellness becomes measurable, it transforms from rhetoric into science.”

The new edition builds on the original by featuring expanded chapters on cellular resilience, oxidative stress management and the role of measurable biomarkers in health optimization. The updated content addresses how modern technology enables individuals to move beyond subjective feelings about health to objective, measurable insights about their biological age and cellular function. Dr. Chang draws from his experience guiding Nu Skin’s quarter-century commitment to evidence-driven wellness research, including breakthrough technologies like the Prysm iO intelligent wellness platform, a non-invasive skin carotenoid measurement device, which provides intelligent insights into an individual’s nutritional health.

“For years, Dr. Chang’s work has guided Nu Skin’s commitment to evidence-based innovation,” said Ryan Napierski, president and CEO. “What makes this relaunch so timely is how closely the research aligns with where Nu Skin is today as we work toward our vision to become the world’s leading intelligent beauty and wellness platform. This updated edition shows how the concepts introduced more than a decade ago have matured into a fully realized ecosystem — one where intelligent devices, targeted nutrition and personalized insights work together to support healthier aging. We believe this book provides the scientific foundation for the next decade of intelligent beauty and wellness.”

The digital edition of “The Aging Myth” is available through Amazon Kindle and other major online book retailers beginning today for $9.99.

About The Author

Joseph Y. Chang, Ph.D., was appointed chair of the Nu Skin Scientific Advisory Board in 2024. Prior to that, he served as Nu Skin’s chief scientific officer and executive vice president of product development for 18 years. A prolific author, Dr. Chang has published numerous articles, reviews and books on pharmacological research, including the New York Times best seller, The Aging Myth. With over 35 years of experience in the pharmaceutical and dietary supplement industries, Joe enjoys a comprehensive knowledge of both industries. Prior to the acquisition of Pharmanex by Nu Skin Enterprises in 1998, he served as the vice president of clinical studies and pharmacology at Pharmanex.

He has also held various research management positions at Wyeth-Ayerst, Rhone Poulenc Rorer and other biotechnology companies, where he was involved in researching natural products for arthritis and immunosuppressive treatment. He received a B.S. degree from Portsmouth University and a Ph.D. from the University of London.

About Nu Skin Enterprises Inc.

The Nu Skin Enterprises Inc. (NYSE: NUS) family of companies includes Nu Skin and Rhyz Inc. Nu Skin is an intelligent beauty and wellness company, powered by a dynamic affiliate opportunity platform, which operates in nearly 50 markets worldwide. Backed by more than 40 years of scientific research, the company’s products help people look, feel and live their best with brands including Nu Skin® personal care, Pharmanex® nutrition and ageLOC® anti-aging, which includes an award-winning line of beauty and wellness device systems. Formed in 2018, Rhyz is a synergistic ecosystem of consumer, technology and manufacturing companies focused on innovation within the beauty, wellness and lifestyle categories.

Contacts

Media: media@nuskin.com, (801) 345-6397
Investors: investorrelations@nuskin.com, (801) 345-3577

Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact crypto.news@mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

This week, NFT transaction volume rebounded by 1.27% to US$108.6 million, and the number of buyers and sellers increased by more than 50%.

This week, NFT transaction volume rebounded by 1.27% to US$108.6 million, and the number of buyers and sellers increased by more than 50%.

PANews reported on September 21st that Crypto.news reported that CryptoSlam data showed that NFT market transaction volume increased by 1.27% over the past week, reaching $108.6 million. Market participation has rebounded, with the number of NFT buyers increasing by 53.24% to 276,735 and the number of NFT sellers increasing by 67.19% to 206,669. However, the number of NFT transactions decreased by 6.65% to 1,630,579. Ethereum network transaction volume reached $46.7 million, a 42.85% surge from the previous week. Mythos Chain network transaction volume reached $12.15 million, down 21.91%. Bitcoin network transaction volume reached $9.82 million, down 2.17%. This week's high-value transactions include: BOOGLE sold for 1,380 SOL ($324,846 USD) CryptoPunks #8521 sold for 55.48 ETH ($255,288 USD) CryptoPunks #4420 sold for 56.388 ETH ($254,250) CryptoPunks #2642 sold for 52.1 ETH ($239,735) CryptoPunks #1180 sold for 49.89 ETH ($232,394)
Share
PANews2025/09/21 09:01
XRP’s ‘True Value’ Could Be $32, Says BlackRock Executive

XRP’s ‘True Value’ Could Be $32, Says BlackRock Executive

Robert Mitchnick and Susan Athey’s 2018 study valued XRP up to $32 under adoption scenarios. Bitcoin is trading above the modeled fair value of $93,000 at $112,800, while XRP has remained stagnant around $3. A resurfaced research paper co-authored in 2018 by Robert Mitchnick, now Head of Digital Assets at BlackRock, has drawn fresh attention [...]]]>
Share
Crypto News Flash2025/09/22 16:40
Grayscale’s ‘first multi-crypto asset ETP’ in the works: Will BTC, ETH win?

Grayscale’s ‘first multi-crypto asset ETP’ in the works: Will BTC, ETH win?

The post Grayscale’s ‘first multi-crypto asset ETP’ in the works: Will BTC, ETH win? appeared on BitcoinEthereumNews.com. Key Takeaways What does this approval mean for investors? It allows traditional investors to access diversified exposure to major cryptocurrencies without buying tokens directly. Which cryptocurrencies are included in GDLC? Bitcoin, Ether, XRP, Solana, and Cardano. The U.S. Securities and Exchange Commission (SEC) has greenlit the Grayscale Digital Large Cap Fund (GDLC) for stock exchange trading.  The approval, coinciding with relaxed ETF listing standards, opens the door for traditional investors to access the crypto market more easily and signals growing institutional support. Grayscale CEO Peter Mintzberg weighs in Grayscale CEO Peter Mintzberg confirmed the development on X (formerly Twitter), praising the SEC’s Crypto Task Force for providing much-needed clarity to the sector. He said,  “The Grayscale team is working expeditiously to bring the FIRST multi #crypto asset ETP to market with Bitcoin, Ethereum, XRP, Solana, and Cardano.” He further added,  “Thank you to the SEC #Crypto Task Force for their continued, unmatched efforts in bringing the regulatory clarity our industry deserves.” The newly approved Grayscale Digital Large Cap Fund (GDLC) offers investors exposure to five of the world’s largest cryptocurrencies: Bitcoin [BTC], Ethereum [ETH], Ripple [XRP], Solana [SOL], and Cardano [ADA]. Impact on included tokens Following the announcement, markets reacted positively. BTC traded at $117,153.61 after a 0.69% rise in the past 24 hours, Ether climbed 2.02% to $4,579.73, XRP at $3.10 up by 3.07%, Solana at $245.94 up by 4.78%, and Cardano reached $0.9130 up by 4.85%, per CoinMarketCap. By packaging multiple cryptocurrencies into a single ETP, GDLC allows traditional investors to gain diversified crypto exposure without the need to open exchange accounts or purchase individual tokens. This green light comes just months after the SEC had delayed Grayscale’s plan to convert GDLC from an over-the-counter fund to an ETP listed on NYSE Arca. With approval now granted, the fund is…
Share
BitcoinEthereumNews2025/09/19 12:53

Trade GOLD, Share 1,000,000 USDT

Trade GOLD, Share 1,000,000 USDTTrade GOLD, Share 1,000,000 USDT

0 fees, up to 1,000x leverage, deep liquidity